QuadraMed Pharmacy Release Targets Enhanced Patient Safety And Medication Reconciliation Regulations
04 Diciembre 2006 - 4:27PM
Business Wire
QuadraMed� Corporation (Amex:QD) today announced that the company
expects to complete beta testing of Affinity� Pharmacy v3.15 in
December, and is targeting general availability for clients in
January 2007. The product enhancements in regulatory, integration,
technical and interface functionality developed for this release
will help Affinity HIS (Healthcare Information System) and
QuadraMed Long Term Care Pharmacy users improve patient safety and
meet new prescription reporting requirements. QuadraMed will be
previewing Affinity Pharmacy v3.15 at the ASHP (American Society of
Health-System Pharmacists) Midyear Clinical Meeting and Exhibition,
December 3-7, in Anaheim, California, Booth 2710. The five
healthcare facilities completing beta testing of Affinity Pharmacy
v3.15 report the product�s capabilities for variable dosing and
improved paper MAR content are particularly effective. This version
enables pharmacists to create predefined drug dosing parameters and
attached them to a formulary item and predefined orders. These
parameters can be modified for all types of orders before saving or
activating them, then viewed and/or printed on reports, such as
MARs, that display medication orders. QuadraMed clients using
Affinity Pharmacy v3.15 will experience increased Medication
Reconciliation functionality for greater patient safety and
improved quality of care. These users will have the ability to
automatically capture nursing information from the bedside,
reducing the possibility of ADEs (adverse drug events) by
eliminating the need to re-enter key patient information by the
pharmacy department. The software also provides complete
prescription reports for facility Admissions departments, transfers
from one level of care to another, and a discharge report for
clinicians. QuadraMed plans to beta test a further enhancement for
Affinity Pharmacy in early 2007. It will feature the capability to
generate a Patient Discharge Report, thereby helping clients meet a
JCAHO 2007 Medication Reconciliation goal for this functionality.
Of special interest to long-term care providers, including mental
health facilities using QuadraMed Long Term Care Pharmacy with
v3.15 enhancements, are redesigned charges, prescription refill
history and third party billing, which will streamline billing to
multiple Medicare Part D payers. The software will feature
provision for a new data element, the National Provider
Identification (NPI) number, to be used in billing and claims
adjudication for federal and state transactions. Also included are
the new fields required by ASAP (American Society for Automation in
Pharmacy) rules-based standards, and the related ASAP Code Set, to
support reporting for state prescription (controlled substance)
monitoring programs. QuadraMed Pharmacy products are part of the
Affinity care management product suite, a key foundational
component of QuadraMed�s Care-Based Revenue Cycle� process. This
strategic process enables healthcare organizations to achieve
improved financial performance by leveraging quality of care into
positive financial outcomes, while providing interoperability for
the connected healthcare community and quality measurement. For
information about all QuadraMed products and services, visit
www.quadramed.com or call 800-393-0278. About QuadraMed Corporation
QuadraMed Corporation advances the success of healthcare
organizations through IT solutions that leverage quality care into
positive financial outcomes. As evolving reimbursement scenarios
challenge healthcare organizations to leverage quality of care into
payment, clients committing to QuadraMed�s care-based solutions can
realize market leading financial performance. Using QuadraMed�s
end-to-end solutions to optimize the patient experience and
leverage quality of care into payment, our clients can receive the
proper reimbursement, in the shortest time, at the lowest
administrative cost. Behind our products and services is a staff of
almost 600 professionals whose experience and dedication to service
have earned QuadraMed the trust and loyalty of customers at
approximately 2,000 healthcare provider facilities. To find out
more about QuadraMed, visit www.quadramed.com. Cautionary Statement
on Risks Associated with QuadraMed�s Forward-Looking Statements
This press release contains forward-looking statements, as defined
in Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, by QuadraMed that are subject to
risks and uncertainties. The words "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "may," "should,"
"could," and similar expressions are intended to identify such
statements. Forward-looking statements are not guarantees of future
performance and are to be interpreted only as of the date on which
they are made. QuadraMed undertakes no obligation to update or
revise any forward-looking statement except as required by law.
QuadraMed advises investors that it discusses risk factors and
uncertainties that could cause QuadraMed�s actual results to differ
from forward-looking statements in its periodic reports filed with
the Securities and Exchange Commission ("SEC"). QuadraMed�s SEC
filings can be accessed through the Investor Relations section of
our website, www.quadramed.com, or through the SEC�s EDGAR Database
at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833). QuadraMed
and Affinity are registered trademarks of QuadraMed Corporation.
Care-Based Revenue Cycle is a trademark of QuadraMed Corporation.
All other trademarks are the property of their respective holders.
QuadraMed(R) Corporation (Amex:QD) today announced that the company
expects to complete beta testing of Affinity(R) Pharmacy v3.15 in
December, and is targeting general availability for clients in
January 2007. The product enhancements in regulatory, integration,
technical and interface functionality developed for this release
will help Affinity HIS (Healthcare Information System) and
QuadraMed Long Term Care Pharmacy users improve patient safety and
meet new prescription reporting requirements. QuadraMed will be
previewing Affinity Pharmacy v3.15 at the ASHP (American Society of
Health-System Pharmacists) Midyear Clinical Meeting and Exhibition,
December 3-7, in Anaheim, California, Booth 2710. The five
healthcare facilities completing beta testing of Affinity Pharmacy
v3.15 report the product's capabilities for variable dosing and
improved paper MAR content are particularly effective. This version
enables pharmacists to create predefined drug dosing parameters and
attached them to a formulary item and predefined orders. These
parameters can be modified for all types of orders before saving or
activating them, then viewed and/or printed on reports, such as
MARs, that display medication orders. QuadraMed clients using
Affinity Pharmacy v3.15 will experience increased Medication
Reconciliation functionality for greater patient safety and
improved quality of care. These users will have the ability to
automatically capture nursing information from the bedside,
reducing the possibility of ADEs (adverse drug events) by
eliminating the need to re-enter key patient information by the
pharmacy department. The software also provides complete
prescription reports for facility Admissions departments, transfers
from one level of care to another, and a discharge report for
clinicians. QuadraMed plans to beta test a further enhancement for
Affinity Pharmacy in early 2007. It will feature the capability to
generate a Patient Discharge Report, thereby helping clients meet a
JCAHO 2007 Medication Reconciliation goal for this functionality.
Of special interest to long-term care providers, including mental
health facilities using QuadraMed Long Term Care Pharmacy with
v3.15 enhancements, are redesigned charges, prescription refill
history and third party billing, which will streamline billing to
multiple Medicare Part D payers. The software will feature
provision for a new data element, the National Provider
Identification (NPI) number, to be used in billing and claims
adjudication for federal and state transactions. Also included are
the new fields required by ASAP (American Society for Automation in
Pharmacy) rules-based standards, and the related ASAP Code Set, to
support reporting for state prescription (controlled substance)
monitoring programs. QuadraMed Pharmacy products are part of the
Affinity care management product suite, a key foundational
component of QuadraMed's Care-Based Revenue Cycle(TM) process. This
strategic process enables healthcare organizations to achieve
improved financial performance by leveraging quality of care into
positive financial outcomes, while providing interoperability for
the connected healthcare community and quality measurement. For
information about all QuadraMed products and services, visit
www.quadramed.com or call 800-393-0278. About QuadraMed Corporation
QuadraMed Corporation advances the success of healthcare
organizations through IT solutions that leverage quality care into
positive financial outcomes. As evolving reimbursement scenarios
challenge healthcare organizations to leverage quality of care into
payment, clients committing to QuadraMed's care-based solutions can
realize market leading financial performance. Using QuadraMed's
end-to-end solutions to optimize the patient experience and
leverage quality of care into payment, our clients can receive the
proper reimbursement, in the shortest time, at the lowest
administrative cost. Behind our products and services is a staff of
almost 600 professionals whose experience and dedication to service
have earned QuadraMed the trust and loyalty of customers at
approximately 2,000 healthcare provider facilities. To find out
more about QuadraMed, visit www.quadramed.com. Cautionary Statement
on Risks Associated with QuadraMed's Forward-Looking Statements
This press release contains forward-looking statements, as defined
in Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, by QuadraMed that are subject to
risks and uncertainties. The words "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "may," "should,"
"could," and similar expressions are intended to identify such
statements. Forward-looking statements are not guarantees of future
performance and are to be interpreted only as of the date on which
they are made. QuadraMed undertakes no obligation to update or
revise any forward-looking statement except as required by law.
QuadraMed advises investors that it discusses risk factors and
uncertainties that could cause QuadraMed's actual results to differ
from forward-looking statements in its periodic reports filed with
the Securities and Exchange Commission ("SEC"). QuadraMed's SEC
filings can be accessed through the Investor Relations section of
our website, www.quadramed.com, or through the SEC's EDGAR Database
at www.sec.gov (QuadraMed has EDGAR CIK No. 0001018833). QuadraMed
and Affinity are registered trademarks of QuadraMed Corporation.
Care-Based Revenue Cycle is a trademark of QuadraMed Corporation.
All other trademarks are the property of their respective holders.
Quadramed (AMEX:QD)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Quadramed (AMEX:QD)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024